A European Collaborative Study of the Role of CyBorD in the Up-Front Treatment of AL Amyloidosis
CME INFORMATION

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unprecedented and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and data sets to consider but they are also severely restricted in their ability to review and interrogate the raw findings.

To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets on novel agents and salvage therapeutic options for the treatment of relapsed or refractory multiple myeloma (MM) and Waldenström macroglobulinemia (WM), high-risk smoldering MM (SMM) and the front-line management of AL amyloidosis from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts may be applied to routine clinical care. This activity will assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES

- Evaluate the final efficacy and safety results from the Phase I/II 1703 study of elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed/refractory MM.
- Appraise recent clinical research findings on the effectiveness of the monoclonal anti-CD38 antibodies SAR650984 and daratumumab in combination with lenalidomide and dexamethasone in relapsed/refractory MM.
- Investigate the efficacy and safety of ibrutinib as a single agent or in combination with dexamethasone in relapsed or relapsed/refractory MM.
- Compare and contrast the benefits and risks of lenalidomide and low-dose dexamethasone with or without carfilzomib for patients with high-risk SMM.
- Analyze the role of front-line cyclophosphamide in combination with bortezomib and dexamethasone (CyBorD) in AL amyloidosis.
- Assess the safety and efficacy of the proteasome inhibitor oprozomib as a single agent in the treatment of WM.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCAS2015/6/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ola Landgren, MD, PhD
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York
Contracted Research: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacies Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Seattle Genetics and Takeda Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: May 2015
Expiration date: May 2016
One of my favorite days of the year occurs every April when the American Society of Clinical Oncology (ASCO) releases their iPlanner for the upcoming annual meeting that provides a first glimpse at the titles of all the oral abstracts that will be presented during the conference. This year my review quickly established that in the world of solid tumors there would be many highlights, including the long-awaited MARIANNE report evaluating pertuzumab and T-DM1 in HER2-positive breast cancer and a ton of impressive checkpoint inhibitor papers in lung cancer (squamous and nonsquamous), melanoma and a number of other diseases.

In terms of hematologic cancers, ASCO is always good for a few headline grabbers, and in reviewing the papers, my attention was immediately drawn to the first abstract in the multiple myeloma (MM) oral session — the Phase III ELOQUENT-2 trial in relapsed/refractory (RR) disease. The study, one of the most anticipated in MM in many years, randomized patients to lenalidomide (len)/dexamethasone (dex) alone or combined with the novel monoclonal antibody elotuzumab (elo).

This was definitely not the first time I became aware ahead of time that an important new data set was about to be presented, and as usual I was desperately curious to find out the results. About a week later I had my chance when the principal investigator, Dr Sagar Lonial, participated in a symposium we were doing as part of our always rewarding annual visit to the Oncology Nursing Society Congress. However, as usual my hopes were crushed by a strict embargo, and Sagar was a complete stone-wall Buddha sphinx, rebuffing all my attempts to squeeze the information out of him and leaving me totally clueless whether the study proved what earlier smaller trials suggested, namely that a special synergy exists between this antibody, which has no single-agent activity, and len.

Fast forward to a week ago, when ASCO released online all but the late-breaking abstracts. My first click was to ELOQUENT-2, and to my delight, elo/len/dex resulted in a 30% reduction in the risk of disease progression and also a mortality benefit. While we most definitely need to see the data and hear Sagar and the rest of the myeloma community’s take, if first impressions are any indication it could be that finally a cancer of cells that produce antibodies is soon going to have one as part of its treatment.
However, until the fun begins in Chicago, there is still much work to be done, and this issue of our American Society of Hematology (ASH) review series highlights a number of new directions in the treatment of MM, including antibodies, and several other related (at least in terms of who manages them) diseases, including Waldenström macroglobulinemia and AL amyloidosis.

**Monoclonal antibodies in MM**

- **Elo/len/dex**

After years of asking investigators to explain how immunomodulating drugs work (and still not completely understanding the answer), I suspect that elo may be even more of a challenge. Signaling lymphocytic activation molecule F7 (SLAMF7) is a glycoprotein that is highly expressed on MM and natural killer (NK) cells but not on normal tissue. As a monoclonal antibody targeted against SLAMF7, elo is thought to directly activate and engage NK cells and selectively target SLAMF7-expressing MM cells for destruction.

---

Elotuzumab works via a dual mechanism of action by both directly activating natural killer cells and through antibody-dependent cell-mediated cytotoxicity to cause targeted myeloma cell death.

Courtesy of Sagar Lonial, MD
As we learn more about the biologic basis of the apparently important synergy of len and elo, ongoing trials are evaluating this approach clinically. At ASH we saw Paul Richardson’s report of 73 patients with RR MM who were treated with this regimen in the Phase II portion of the 1703 study, revealing similar encouraging outcomes as a prior single-arm study (response rate: 84%) with good tolerability. The bottom line now is that on Tuesday, June 2nd at 9:45 AM in the McCormick Place Convention Center, we will find out just how much it helps patients.

**Anti-CD38 antibodies with len/dex**

While elo may be first with Phase III data, among MM investigators there is perhaps even more excitement about anti-CD38 agents, particularly daratumumab (dara) and the as yet nameless SAR650984 (sar). For quite some time now on our CME programs we have been hearing about the single-agent activity of these compounds, and I can recall a number of cases with impressive responses after disease progression on multiple therapies. However, the future of MM treatment seems to be combinations, which are firmly entrenched in the induction setting and gaining traction in RR disease. Thus it is no surprise to see strategies like the 2 featured here of combining these antibodies with len/dex and producing very good outcomes (77% very good partial response or greater with dara/len/dex; 64.5% overall response rate with sar/len/dex). Many investigators, including Dr Lonial, believe that depth of response is critical in MM, and the hope has been that bringing in new classes of effective agents might push the disease into a more prolonged remission, also raising the possibility of cure as a treatment goal. Much more to come.
Ibrutinib in MM

Ibrutinib has been a revelation in terms of efficacy and activity across many variants of non-Hodgkin lymphoma, and when laboratory evidence emerged regarding the activation of Bruton tyrosine kinase in MM cells, there was optimism that this drug might play an important role in the management of this disease. Unfortunately, at ASH we saw data from a Phase II trial evaluating ibrutinib as a single agent or in combination with dex for patients with RR MM that demonstrated modest, somewhat underwhelming activity (clinical benefit rate of 8% with single-agent ibrutinib and 25% with the combination of ibrutinib/dex). Although further research is ongoing, few are optimistic that ibrutinib in MM will be anything close to what it is in chronic lymphocytic leukemia and mantle-cell lymphoma.

High-risk smoldering MM (SMM)

Although the standard therapy for these patients continues to be observation, a variety of predictive factors identify a subgroup with at least a 75% risk of disease progression at 5 years. As such, there continues to be significant interest in whether early intervention could help improve outcomes for these patients. In this regard, in San Francisco we saw more follow-up from the landmark Spanish Phase III QUIREDEX trial that had previously demonstrated an important benefit with the use of len/low-dose dex. With a median follow-up of 64 months, these findings continue to be positive, revealing that progression to symptomatic disease occurred in 25% of patients who received treatment versus 85% in the control group (overall survival rate at 7 years: 94% versus 64% with a hazard ratio of 4.6 and \( p = 0.001 \)).

The NCI group formerly led by Ola Landgren, MD, PhD decided to take things even further and evaluate a triplet regimen, in this case carfilzomib/len/dex, followed by len maintenance in patients with high-risk SMM. Among the 12 patients who received treatment in this manner, 10 became MRD-negative after 8 cycles as determined by next-generation sequencing, which, by way of indirect comparison, appears to be an even greater benefit than the approach taken by the Spanish.

Importantly, a number of ongoing studies are pursuing these encouraging leads, including a major ECOG trial chaired by Dr Lonial in an attempt to confirm the Spanish len/dex data, and it could very well be that one day soon treating high-risk SMM will become part of practice.

Cyclophosphamide/bortezomib/dex (CyBorD) in AL amyloidosis (ALA)

Based on the results from a number of smaller trials, CyBorD has become one of the most commonly used up-front regimens for the treatment of this disease. To further confirm the benefits of this approach, 2 major ALA centers in London, England and Pavia, Italy prospectively collected findings from 230 cases of patients with newly diagnosed disease who received this regimen. The result is the largest data set ever reported with up-front CyBorD in the disease, from which a number of important observations can be made. Notably, of 30 patients with Stage I ALA (no cardiac...
involvement), 80% responded (56% complete response/very good partial response) and there were no deaths with a median of 25 months of follow-up. Median survival of all patients was 72 months.

However, it appears that cardiac stage was the main determinant of survival, and patients with advanced heart disease (defined as those with N-terminal pronatriuretic peptide type B >8,500 ng/L) had poor outcomes, although 37% did achieve a response and seemed to fare better overall. The key takeaway from this data set is that due to the high clonal response and excellent outcome in early-stage ALA, CyBorD remains a preferred induction option and further research is needed to determine whether autologous stem cell transplant should be initiated as part of up-front treatment.

**Novel agents in Waldenström macroglobulinemia (WM)**

On January 29, 2015, ibrutinib became the first ever agent approved by the FDA for the management of WM. This significant milestone, along with emerging data indicating the activity of a number of other established and novel therapeutics, has breathed new life and interest into the treatment of this rare disease. At ASH we saw several examples of work attempting to move the field forward, including a Phase I/II trial evaluating **single-agent len** in 17 patients with RR WM. Thirty-six percent of these individuals responded to therapy, and with a median follow-up of 36 months, 35% of patients had a progression-free survival greater than 24 months.

Similarly, we also saw data from a Phase Ib/II trial evaluating the oral proteasome inhibitor oprozomib, which, like its intravenous cousin carfilzomib, appears to have significant efficacy in this disease. Notably, responses were observed in 5 of 7 patients refractory to bortezomib, and treatment was reasonably well tolerated, although some of the gastrointestinal toxicity that has plagued this agent was observed. To potentially eliminate this troubling side effect there is great interest in evaluating an extended-release formulation of the agent in both MM and WM.

Next, on the final issue of our ASH series, we check out papers on non-Hodgkin lymphoma, including the evaluation of anti-CD20 maintenance treatment in mantle-cell lymphoma.

Neil Love, MD

Research To Practice

Miami, Florida
A European Collaborative Study of the Role of CyBorD in the Up-Front Treatment of AL Amyloidosis

Presentation discussed in this issue


Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis

Palladini G et al.

Proc ASH 2014;Abstract 305.
Background

• Early small studies have reported unprecedented response rates for patients with systemic light chain (AL) amyloidosis treated with the combination of cyclophosphamide, bortezomib and dexamethasone (CyBorD) (Blood 2012;119 (19):4391).
  – Response rate: 94%
  – Complete hematologic response: 71%
• Based on these results, CyBorD has become one of the most commonly prescribed front-line regimens in AL amyloidosis outside of clinical trials.
• Subsequently, it was shown that CyBorD is unable to overcome the poor prognosis of patients with advanced cardiac disease (Blood 2013;121(17):3420-7).
• **Study objective:** To assess the role of CyBorD as up-front treatment for patients with AL amyloidosis.

Palladini G et al. *Proc ASH* 2014;Abstract 305 (Abstract only).

Study Methods

• Prospectively maintained databases of the London National Amyloidosis Centre and the Pavia Amyloidosis Research and Treatment Center were searched for newly diagnosed patients who received CyBorD between 2006 and 2013.
• Number of patients identified (n = 230)
  – Median estimated glomerular filtration rate: 82 mL/min
  – Median bone marrow plasma cell infiltrate: 12%
  – Difference between involved and noninvolved free light chain (dFLC): 248 mg/L
• Cyclophosphamide: 300 mg/m² on d1, 8, 15
• Bortezomib: 1.0 mg/m² q1wk to 1.3 mg/m² twice weekly
• Dexamethasone: Mostly 10, 20 or 40 mg per week
  – 69 patients (30%) received ≥160 mg/week
• Median number of cycles: 4 (range, 1-8)

Palladini G et al. *Proc ASH* 2014;Abstract 305 (Abstract only).
### Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N = 230</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (range)</td>
<td>60 years (38-85)</td>
</tr>
<tr>
<td>Involved organs: Heart</td>
<td>169 (73%)</td>
</tr>
<tr>
<td>Kidney</td>
<td>149 (65%)</td>
</tr>
<tr>
<td>Soft tissues</td>
<td>35 (15%)</td>
</tr>
<tr>
<td>Liver</td>
<td>25 (11%)</td>
</tr>
<tr>
<td>Peripheral nervous system</td>
<td>6 (3%)</td>
</tr>
<tr>
<td>Cardiac disease: Stage I</td>
<td>41 (18%)</td>
</tr>
<tr>
<td>Stage II</td>
<td>77 (33%)</td>
</tr>
<tr>
<td>Stage III</td>
<td>112 (49%)</td>
</tr>
<tr>
<td>N-terminal pronatriuretic peptide type B &gt;8,500 ng/L</td>
<td>51 (22%)</td>
</tr>
</tbody>
</table>

- 201 patients with measurable disease


### Response in Intent-to-Treat (ITT) Population

<table>
<thead>
<tr>
<th>Response rate (All ITT)</th>
<th>n = 201*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematologic response</td>
<td>62%</td>
</tr>
<tr>
<td>Complete response (CR)</td>
<td>42 (21%)</td>
</tr>
<tr>
<td>Very good partial response (VGPR)</td>
<td>45 (22%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiac Stage I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematologic response</td>
</tr>
<tr>
<td>≥VGPR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiac Stage IIIB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematologic response</td>
</tr>
<tr>
<td>≥VGPR</td>
</tr>
</tbody>
</table>

* Evaluatable patients (40 deaths before response evaluation)
- Response was affected by cardiac stage.

Palladini G et al. *Proc ASH 2014; Abstract 305.*
Response by NT-proBNP and Second-Line Therapy

- Patients with N-terminal pronatriuretic peptide type B (NT-proBNP) >8,500 ng/L who achieved a response: 37%
  - Patients alive at 12 months: 28%
    - Responders in this group: 85%
      - Achieved CR/VGPR: 69%
- The most common second-line treatments:
  - Autologous stem cell transplant (ASCT) (n = 17)
    - Response rate: 65%
      - CR: 47%
  - Lenalidomide/dexamethasone (n = 20)
    - Response rate: 65%
      - CR: 10%

Palladini G et al. Proc ASH 2014;Abstract 305 (Abstract only).

Cardiac and Renal Response

- Patients with renal responses: 27%
- Cardiac response decreased with increasing cardiac stage:
  - In patients with Stage II disease: 29%
  - In patients with Stage IIIA disease: 17%
  - In patients with Stage IIIB disease: 4%

Palladini G et al. Proc ASH 2014;Abstract 305.
Survival Outcomes

- Median survival for all patients: 72 months
- After a median follow-up of 25 months:
  - Deaths: 94 (41%)
  - Estimated 5-year survival:
    - For patients with Stage I disease: 100%
    - For patients with Stage II disease: 52%
    - For patients with Stage III disease: 27%

Palladini G et al. Proc ASH 2014;Abstract 305 (Abstract only).

Treatment Outcomes

- Cardiac staging was the main factor affecting survival.
- There were no deaths among patients with Stage I disease without cardiac involvement.
- Survival was similar between patients with Stage II and Stage IIIA disease
  - Indicating that this regimen can rescue and improve survival of some patients with advanced disease
- However, the survival of patients with advanced cardiac Stage IIIB disease was still poor
  - Median survival: 7 months

Palladini G et al. Proc ASH 2014;Abstract 305.
Treatment Outcomes (continued)

- Response improved survival only in patients with Stage II or Stage IIIA disease, with best survival outcomes in those who achieved VGPR or CR.
- There was an improvement of survival in patients who achieved PR.
- Patients with Stage IIIB disease who survived until the landmark analysis at 3 months survived longer if they responded to treatment.

Palladini G et al. *Proc ASH* 2014;Abstract 305.

Author Conclusions

- This is the largest study of CyBorD treatment in AL amyloidosis.
- This study confirms that CyBorD is remarkably effective in patients at low risk, with 56% CR/VGPR and no deaths observed in patients with Stage I disease.
- Unfortunately, outcomes in patients with advanced cardiac disease were poor.
  - However, 28% of these patients who achieved a CR or VGPR had improved survival, showing the importance of striving for a good response even in this poor-risk group.
- The very high clonal response and excellent outcome in early-stage AL with CyBorD therapy confirm its place as a regimen of choice for this group and raise the need for a randomized trial assessing the role of up-front ASCT in this era of novel agent-based therapy in AL amyloidosis.

Palladini G et al. *Proc ASH* 2014;Abstract 305 (Abstract only).
Investigator Commentary: A European Collaborative Study to Determine the Role of Up-Front CyBorD in AL Amyloidosis

This is an important study of 230 patients with AL amyloidosis who received up-front CyBorD therapy. Most oncologists treat AL amyloidosis with CyBorD based on information from a series of smaller studies. Hence, this large study was initiated and showed that 56% of patients with cardiac Stage I disease achieved VGPR or better. For patients with advanced cardiac disease, the outcome was worse, but 28% of these patients achieved CR or VGPR. For these patients, survival was improved. One could evaluate these results from different perspectives and say that it’s better to administer CyBorD to patients with low-risk disease than to those at high risk. On the other hand, for high-risk disease, whatever therapy is used will result in a worse outcome. Also, one could probably interpret the results to say that this therapy works for both high-risk and low-risk disease, but, as expected, it’s even better for patients with low-risk disease.

Such deep responses with this regimen, similar to those seen in newly diagnosed and relapsed multiple myeloma, raise the question of what the role is for up-front ASCT in AL amyloidosis. The high clonal response and excellent outcome with CyBorD in early-stage AL amyloidosis necessitate a randomized study of up-front versus delayed ASCT in this setting.

Interview with Ola Landgren, MD, PhD, February 9, 2015